Latest research on Darunavir

Darunavir is a protease inhibitor used to treat HIV. It acts on the HIV aspartyl protease which the virus needs to cleave the HIV polyprotein into its functional fragments.

Darunavir indications

Single doses of Darunavir up to 3200 mg and atazanavir up to 1200 mg have been administered to healthy volunteers with no apparent ill effects [32,33]. [source, 2016]
A minority would replace EFV with raltegravir, Nevirapine, atazanavir or Darunavir, citing potency or concerns about EFV side effects. [source, 2016]
We identified eight studies comparing the cost-effectiveness analyses of the specific HAART regimens; two compared Darunavir + low-dose Ritonavir (DRV/r) with Lopinavir + Ritonavir. [source, 2015]
This analysis provides information on lipid outcomes at 48 weeks from phase IIb and III controlled studies within the dolutegravir development programme, and allows for a comparison of the effect on lipids of dolutegravir versus other classes of treatments for HIV, including non-NRTIs (NNRTIs; Efavirenz), boosted protease inhibitors (ritonavir-boosted Darunavir), and a first-generation INSTI, raltegravir. [source, 2015]
Dolutegravir also demonstrated an effect on serum lipids that was smaller than that observed with Efavirenz or boosted Darunavir, regardless of the choice of NRTI backbone. [source, 2015]
At low Darunavir concentrations, the most common variant (77V93I) underwent effective autoprocessing and the full length precursor was therefore not detectable. [source, 2015]
This suggests that the 77I variant alone increases the precursor’s sensitivity to Darunavir and 93V alone decreases precursor’s sensitivity to Darunavir, whereas a functional interaction between the two complemented these two opposite effects. [source, 2015]
Furthermore, precursor autoprocessing profiles in response to Darunavir, a PR inhibitor, demonstrated that the individual 77I and 93V variants display contrasting effects on this activity, while the 77I93V double variant shows a phenotype between the two individual variants that is also similar to that of 77V93I, the most common variation (Fig 6B). [source, 2015]
This was used to confirm past data and to investigate the effects of previously un-assessed antiretrovirals such as Darunavir, Lopinavir, and etravirine. [source, 2015]
Therapy by means of protease inhibitors (PI) also frequently leads to lipodystrophy and metabolic disorders, which is the indication for drug replacement with the other one such as Nevirapine (non-nucleoside reverse transcriptase inhibitor – NNRTI) or a new generation PI drug (Darunavir or atazanavir) [25]. [source, 2015]